news

Recent press releases:

• December 06, 2012: Two Posters and Two Oral Presentations on NOXXON Compounds at 2012 ASH Conference
• December 04, 2012: NOXXON Initiates Phase IIa of Anti-Hepcidin Spiegelmer NOX-H94
• September 26, 2012: NOXXON Initiates Phase IIa Trial of anti-CXCL12/SDF-1 Spiegelmer NOX-A12 in Second Oncology Indication: Multiple Myeloma

Latest publications:

• Hematopoietic stem and progenitor cell mobilization in mouse and man by a first-in-class mirror-image oligonucleotide inhibitor of CXCL12.
  Clinical Pharmacology and Therapeutics. 2013.
  read article on nature.com
  
• Targeting complement component 5a promotes vascular integrity and limits airway remodeling.
  PNAS. 2013.
  read article on pnas.org
  
• The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys.
  Blood. 2013, Vol 121(12), 2311-15.
  read article on bloodjournal.hematologylibrary.org
  

NOXXON presentation:

• Bio 2012